乳腺癌是全球女性中最普遍的癌症之一，也是导致女性癌症死亡和残疾的主要原因之一。乳腺癌治疗已应用多种疗法，但长期生存率仍较低。尽管顺铂已被广泛应用于癌症治疗，但化疗耐药仍对预后产生影响。收集了经顺铂处理与未处理的乳腺癌细胞株MDA-MB-231以及来自癌症基因组图谱计划（TCGA）的样本信息，筛选出它们共同的参数以及对患者预后的影响。采集了2017年至2020年在柳州市人民医院乳腺与甲状腺外科就诊和治疗的乳腺癌患者手术切除组织切片，并进行随访。通过一系列实验结合临床信息，测试了该靶点的可靠性。我们发现，在乳腺癌细胞株中，ZNF268的高表达显著增强了对顺铂的敏感性，而低表达的效果相反。此外，在顺铂化疗后，ZNF268高表达的患者预后明显较差。乳腺癌患者顺铂化疗后的ZNF268表达水平可能成为预测患者对顺铂耐药性的潜在靶点。本研究为改善乳腺癌治疗和生存率提供了新的思路。© 2023 The Authors. Published by Elsevier Ltd.

Breast cancer is one of the most prevalent cancers in females worldwide and is one of the leading causes of cancer death and disability in women. Multiple therapies have been applied to breast cancer treatment; however, the long-term survival rate remains low. Although cisplatin has been widely utilized for cancer therapy, chemoresistance still influences the outcome.After collecting the breast cancer cell line MDA-MB-231 treated with or without cisplatin and sample information from The Cancer Genome Atlas Program (TCGA), we screened out their common parameters and influences on the prognoses of patients' potential targets. Surgical excisional tissue sections of patients with breast cancer who were admitted and treated in the Department of Breast and Thyroid Surgery, Liuzhou People's Hospital from 2017 to 2020 was collected and follow up. After a series of assays combined with clinical information, we tested the reliability of the target.We found that a high expression level of ZNF268 in breast cancer cell lines significantly enhances the sensitivity to cisplatin, contrary to the effects of low expression. Furthermore, a significantly worse prognosis was observed in patients with a high expression of ZNF268 after cisplatin chemotherapy.The expression level of ZNF268 in breast cancer patients after cisplatin chemotherapy may become a potential target to predict the chemoresistance of patients to cisplatin. This study provides a novel idea for improving breast cancer treatment and survival rates.© 2023 The Authors. Published by Elsevier Ltd.